Jpmorgan Chase & CO Inozyme Pharma, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding INZY
# of Institutions
90Shares Held
53MCall Options Held
3.7KPut Options Held
5.8K-
Adage Capital Partners Gp, L.L.C. Boston, MA5.67MShares$15.4 Million0.05% of portfolio
-
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA4.49MShares$12.2 Million18.53% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA4.28MShares$11.6 Million2.12% of portfolio
-
Eventide Asset Management, LLC Boston, MA4.13MShares$11.2 Million0.38% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD3.8MShares$10.3 Million0.68% of portfolio
About Inozyme Pharma, Inc.
- Ticker INZY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,145,700
- Market Cap $109M
- Description
- Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...